NCT04987112View on ClinicalTrials.gov

Intratumoral CAN1012(Selective TLR7 Agonist) in Subjects With Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

January 20, 2022

Primary Completion Date

December 30, 2024

Study Completion Date

December 30, 2024

Conditions
Solid TumorCancer Metastatic
Interventions
DRUG

CAN1012

CAN1012 IT injection (once every 4 weeks)

Trial Locations (2)

97213

RECRUITING

Providence Cancer Institute, Portland

02466

RECRUITING

CanWellPharma, Woburn

Sponsors
All Listed Sponsors
lead

CanWell Pharma Inc.

INDUSTRY